Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0730
Full Text
Open PDFAbstract
Available in full text
Date
March 3, 2016
Authors
Publisher
American Association for Cancer Research (AACR)